Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blinded, Placebo-Controlled, Randomized, Phase 1/2a Clinical Study to Test the Safety and Efficacy of a Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound

NCT07304024 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.

NCT NCT07304024
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07304024 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blinded, Placebo-Controlled, Randomized, Phase 1/2a Clinical Study to Test the Safety and Efficacy of a Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound
Lead sponsor
University of Colorado, Denver
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 31, 2025
Completion date
July 31, 2028
Enrollment
344 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

age problem, capd, central auditory disease, central auditory processing disorder, cocktail party skill, cocktail party syndrome, hearing, hearing abnormality, hearing disability, hearing disorder, hearing disorders, hearing handicap, hearing impaired, hearing impaired (partially), hearing impairment, hearing impairment, sensorineural, hearing loss, hidden hearing loss, myelin degeneration, myelin integrity, myelinopathy, noise exposure, noise induced hearing loss, noise-induced hearing loss, remyelination, sound perception